EcoDrugPlus

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSSPAG00000020393
Gene Symbol: GSK3B
3 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSSPAG00000023137
Gene Symbol: LOC103362704
3 Cross references
186 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSSPAG00000007044
Gene Symbol: LOC103362869
3 Cross references
187 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSSPAG00000005191
Gene Symbol: LOC103357128
2 Cross references
135 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSSPAG00000010437
Gene Symbol: LOC103369603
2 Cross references
155 Possible Orthologues:

Granzyme B-Like

Ensembl ID : ENSSPAG00000018392
Gene Symbol: LOC103371128
2 Cross references
988 Possible Orthologues:

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSSPAG00000002087
Gene Symbol: LOC103360505
3 Cross references
232 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSSPAG00000010121
Gene Symbol: GHRHR
4 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor Type 1-Like

Ensembl ID : ENSSPAG00000002167
Gene Symbol: LOC103356052
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSSPAG00000021171
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSSPAG00000012518
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSSPAG00000021151
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).